Navigation Links
Israel's Prestigious President's Conference to Feature Oramed Pharmaceuticals' Revolutionary Oral Insulin Capsule

Oramed is one of 60 Companies Selected to Participate at the "Facing

Tomorrow" Conference Marking the Country's 60th Birthday

JERUSALEM, Israel, May 6 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP), a developer of oral delivery systems, has been selected for the first annual Presidential conference, "Facing Tomorrow," as one of the 60 "enterprises of tomorrow" representing the future face of Israel. The monumental event is being held to mark the country's sixtieth birthday.

Additionally, Oramed was one of six companies chosen to be featured in a video presentation at the conference's opening event. The conference will be attended by global political and business leaders, including Israeli Prime Minister Ehud Olmert, President George W. Bush and Google founder Sergey Brin.

"The selection of Oramed as one of the companies to change the face of tomorrow is a great honor," said Nadav Kidron, CEO of Oramed Pharmaceuticals. "Being chosen for the conference illustrates the potential of our technology to make a significant difference for millions of diabetics around the world."

The conference will be held May 13-15 at the Jerusalem International Convention Center.

For more information on the conference, please visit the conference's website at:

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is an Israeli-based company focused on the development of oral delivery solutions based on proprietary technology. Oramed is currently developing an orally ingestible insulin capsule for the treatment of diabetes. The oral administration of insulin is more physiological than the current delivery method, mimicking the natural path of insulin throughout the body. The company is also pursuing the development of oral delivery solutions for drugs and vaccines presently delivered via injection.

For more information, please visit our website at:

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Tara Horn

Cell: +972-54-33-44-318

Office: +972-2-566-0001


Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-46-76-950

Office: +972-2-589-2003


SOURCE Oramed Pharmaceticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Fraunhofer and Boston University Hosted Prestigious SME Tour
2. Prestigious Scientific Leaders Join InterWest Advisory Committee
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. Launch of New, Prestigious Infertility and Gynaecology Research GrAnt (FRIGGA)
5. Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service
6. Research by Case Western Reserve University, VA earns cover of prestigious science publication
7. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
8. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
9. Prestigious Bioethics Award for Scholar from Mexico
10. Physics professor lauded for NSF efforts with prestigious award
11. Physics professor lauded for NSF efforts with prestigious award
Post Your Comments:
(Date:10/8/2015)... Fla. , Oct. 8, 2015   Intrexon ... synthetic biology, today announced the appointment of Joseph ... Environment Sector, succeeding Nir Nimrodi who continues ... Vaillancourt will direct Intrexon,s endeavors to generate sustainable, biologically ... America , where he held a variety of ...
(Date:10/8/2015)... IRVINE, Calif. , Oct. 8, 2015 ... announced its expansion into the North American market with ... Asia and Europe ... a pioneer of Target Enrichment methodology and sample preparation ... or NGS, facilitates both hereditary and somatic genetic testing ...
(Date:10/8/2015)... -- The ALS Association, in partnership with Prize4Life, is pleased ... communication technology solutions for people living with ALS. ... lateral sclerosis) is a progressive neurodegenerative disease that affects ... cord. Eventually, people with ALS lose the ability to ... total paralysis and death within two to five years ...
(Date:10/8/2015)... ... 08, 2015 , ... ProMIS Neurosciences, Inc. (TSX: PMN), announced ... commercialize intellectual property rights belonging to The University of British Columbia (UBC). This ... worldwide rights to intellectual property based on use of the ProMIS™ technology, modifications ...
Breaking Biology Technology:
... ... product immediately, NATICK, Mass., April 14 Boston Scientific,Corporation ... Labor,and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular,lead ... failure. The Company also received reimbursement approval for,the lead from ...
... SGP ) is scheduled to announce its sales and ... 23, 2008., At 8 a.m. (EDT) on that ... for the 2008 first quarter and provide an update ... Fred Hassan,Schering-Plough,s chairman and CEO, and other members of ...
... For 88 percent of,companies, front-line and mid-level leaders ... variety of development skills but focus,strongly on techniques ... only half of executive-level sales leaders attend the ... and,training, according to a member-driven research study conducted ...
Cached Biology Technology:
(Date:9/24/2015)... September 24, 2015 ... 2015 Kerv ( ... lanserar idag världens första kontaktlösa betalningsring på ... 77 000 GBP för massproduktion via crowdfunding.  ... ) , Kerv-bärare kan göra ...
(Date:9/10/2015)... Sept. 10, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... site, Touch of Modern, will feature the Wocket® smart ... th . Touch Of Modern ... designer lifestyle products to its 7.2 million members. Customers ...
(Date:9/2/2015)... YORK , Sept. 2, 2015 ... key concern for enterprises, banks, government organizations, telecommunications, ... and numeric keypads were previously being used to ... introduction of two-factor authentication, wherein individuals could gain ... two different components, such as hardware devices and ...
Breaking Biology News(10 mins):
... -- A team of scientists led by Washington University in ... corn, a crop vital to U.S. agriculture. The researchers have ... that should accelerate efforts to develop better crop varieties to ... , Corn, also known as maize, underlies myriads of ...
... past year, various reports from the United Nations Intergovernmental Panel ... uncertain terms that in order to achieve a stable climate ... increase in CO2 emissions in the coming decades must be ... the IPCC, the maxi-mum amount of CO2 emissions that can ...
... do nearly 1 million people taking cholesterol-lowering statins often ... rare case when a diabetic takes medication for intestinal ... basis for the purported health effects of green tea? ... clinical explanation for these and other physiological mysteries. The ...
Cached Biology News:
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Synaptotagmin, phosphoSer309...
... anti-phospho-PTEN (Ser385) ... amino acid region encompassing the ... (Ser385), Accession ... Quality Assurance: Routinely ...
Allophycocyanin (APC) anti-human CD193 (CCR3, CKR3) 25 tests...
Biology Products: